DeCode's Q1 Revenue Falls 15 Percent as R&D Spending Slides and Loss Widens | GenomeWeb
NEW YORK (GenomeWeb News) — DeCode Genetics today said first-quarter revenues decreased 15 percent as R&D spending dropped 18 percent and losses rose 9 percent.
 
Total receipts for the three months ended March 31 fell to $8.6 million from $10.1 million year over year.
 
DeCode said it also had $11.6 million in deferred revenue at the close of the first quarter, which it will recognize over future periods.
 
R&D spending fell to $12.7 million from $15.5 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.